Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease
- PMID: 19230923
- DOI: 10.1016/j.juro.2008.11.123
Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease
Abstract
Purpose: We determined various sociodemographic predictors of prostate cancer risk category at presentation as assessed by serum prostate specific antigen, cancer grade and tumor stage.
Materials and methods: We performed a retrospective cohort study of 5,939 patients enrolled in the CaPSURE national disease registry database between 1995 and 2007. Prostate cancer risk category was assigned as low, intermediate or high based on diagnostic prostate specific antigen, clinical grade and biopsy Gleason grade. Additionally, a group of men with low grade, limited volume tumors were identified as having clinically insignificant disease. The primary outcome was prostate cancer risk category at presentation. Treatment received vs active surveillance was analyzed as a secondary end point.
Results: Patients who were older, had lower levels of education and had Medicare with or without a supplement instead of private or Veteran's Affairs insurance were more likely to have intermediate and high risk disease than low risk disease. Nonwhite race was associated with high risk disease at presentation. Clinically insignificant disease was more common in men younger than 60 years, those with higher education and income, and those with private insurance. Logistic regression analysis suggested that younger age, higher education and income, and private insurance were related to insignificant disease being detected. Among men with insignificant disease younger age and private insurance were associated with immediate treatment with curative intent.
Conclusions: Unique sociodemographic variables are associated with the clinical risk of prostate cancer at diagnosis and they may influence treatment decisions and outcomes. Patients with insignificant disease may be susceptible to overtreatment due to the indolent nature of the disease. Intermediate and high risk groups, which are associated with poorer outcomes, may be further endangered by late detection of the disease.
Similar articles
-
Prostate cancer outcomes among older men: insurance status comparisons results from CaPSURE database.Prostate Cancer Prostatic Dis. 2008;11(3):280-7. doi: 10.1038/sj.pcan.4501015. Epub 2007 Sep 25. Prostate Cancer Prostatic Dis. 2008. PMID: 17893700
-
Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).J Urol. 2005 May;173(5):1557-61. doi: 10.1097/01.ju.0000154610.81916.81. J Urol. 2005. PMID: 15821485
-
Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.BJU Int. 2008 Mar;101(6):691-7. doi: 10.1111/j.1464-410X.2007.07353.x. BJU Int. 2008. PMID: 18291018
-
A framework for the identification of men at increased risk for prostate cancer.J Urol. 2009 Nov;182(5):2112-20. doi: 10.1016/j.juro.2009.07.018. Epub 2009 Sep 16. J Urol. 2009. PMID: 19758625 Review.
-
Imaging low-risk prostate cancer.Curr Opin Urol. 2008 Jan;18(1):78-86. doi: 10.1097/MOU.0b013e3282f13adc. Curr Opin Urol. 2008. PMID: 18090495 Review.
Cited by
-
Overdiagnosis and overtreatment of prostate cancer.Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9. Eur Urol. 2014. PMID: 24439788 Free PMC article. Review.
-
The effect of socioeconomic status, race, and insurance type on newly diagnosed metastatic prostate cancer in the United States (2004-2013).Urol Oncol. 2018 Mar;36(3):91.e1-91.e6. doi: 10.1016/j.urolonc.2017.10.023. Epub 2017 Nov 15. Urol Oncol. 2018. PMID: 29153624 Free PMC article.
-
Multilevel Factors Associated With Overall Mortality for Men Diagnosed With Prostate Cancer in Florida.Am J Mens Health. 2014 Jul;8(4):316-26. doi: 10.1177/1557988313512862. Epub 2013 Dec 1. Am J Mens Health. 2014. PMID: 24297455 Free PMC article.
-
The example of CaPSURE: lessons learned from a national disease registry.World J Urol. 2011 Jun;29(3):265-71. doi: 10.1007/s00345-011-0658-3. Epub 2011 Feb 24. World J Urol. 2011. PMID: 21347810 Free PMC article.
-
The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.J Natl Compr Canc Netw. 2009 Oct;7 Suppl 7(Suppl 7):S1-29; quiz S30. doi: 10.6004/jnccn.2009.0080. J Natl Compr Canc Netw. 2009. PMID: 19878635 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical